$APTOF

Whitehead Warren sold (to issuer) $57 of APTOF

Whitehead Warren sold (to issuer) 33 shares of Aptose Biosciences Inc. (APTOF) at $1.72 on 2026-06-30.

Original reporting
SEC EDGAR · Whitehead Warren
Published Jul 1, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$APTOF
Neutral
medium confidence
Mentioned
$APTOF
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APTOFNeutralLow
01

Why it matters

The disclosure confirms an insider sale to the issuer at a specified price and date, but provides no new operational, clinical, or financial catalyst.

02

Market read

Traders may note the insider reduced holdings, but the transaction size and buyback-style framing suggest limited tradable impact.

03

What to watch

The filing does not indicate open-market selling intent; the small share count and post-transaction 0 shares reduce the signal-to-noise for traders.

Relevance 3/10Novelty 3/10Timing: filed July 1, 2026 (after-hours/late day) for a June 30 transaction

Background

This is an SEC Form 4 insider transaction disclosure for Aptose Biosciences Inc.

Company-level read

Ticker impact

$APTOFNeutralMedium confidence
Context

Aptose Biosciences insider Whitehead Warren sold 33 shares to the issuer at $1.72/share, leaving 0 shares after the transaction.

Expected impact

Low likelihood of a sustained price move; any reaction would be small and short-lived.

Evidence & confidence

Form 4 is primary-source, but the transaction is small (33 shares) and described as a sale to the issuer with no 10b5-1 plan, which still typically has limited interpretive power versus larger, open-market trades.

Market effects

No sector read-through; this is a single-company, small insider transaction.

None.

None.

Counterpoint

Because the sale is to the issuer, it may reflect mechanical participation in a corporate action (e.g., buyback) rather than a bearish view.

Key entities

  • Aptose Biosciences Inc.

    Subject of the Form 4 insider transaction; insider sold shares to the issuer at $1.72/share.

  • Whitehead Warren

    Reported insider who sold 33 shares to the issuer on June 30, 2026.

Related articles

$APTOFMed

Aptose Biosciences Inc. (APTOF): Completion of Acquisition or Disposition of Assets

Aptose Biosciences Inc. (APTOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0000882361 0000882361 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30,